DCC-2036 (Rebastinib)
Inquiry
| Post Date: | Apr 03,2015 |
| Expiry Date: | Apr 02,2016 |
| Detailed Description: |
Cas No. :1020172-07-9
Quantity: 50g Specs:98% purity Payment Method: T/T, Western Union DCC-2036 is an orally bioavailable small-molecule inhibitor of multiple tyrosine kinases with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor DCC-2036 binds to and inhibits the Bcr-Abl fusion oncoprotein by changing the conformation of the folded protein to disallow ligand-dependent and ligand-independent activation; in addition, this agent binds to and inhibits Src family kinases LYN, HCK and FGR and the receptor tyrosine kinases TIE-2 and VEGFR-2. Multitargeted tyrosine kinase inhibitor DCC-2036 may exhibit more potent activity against T315I Bcr-Abl gatekeeper mutant kinases than other Bcr-Abl kinase inhibitors. The TIE-2 and VEGFR-2 receptor tyrosine kinases regulate angiogenesis, respectively, while the Src family kinases Abl, LYN, and HCK Src regulate a variety of cellular responses including differentiation, division, adhesion, and the stress response. |
| CAS Registry Number: | 1020172-07-9 |
| Company: | Shanghai Sun-shineChemical Technology Co.,Ltd. [ China ] |
| Contact: | Rosie |
| Tel: | +86-027-59253327 |
| Fax: | 0086-27-5925 3326 |
| Email: | sales02@sun-shinechem.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
